Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis

Gut

Volumn 54, Issue 7, 2005, Pages 966-971

  Stremmel, W ^a   Merle, U ^a   Zahn, A ^a   Autschbach, F ^a   Hinz, U ^b   Ehehalt, R ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLCHOLINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED DRUG RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; CHRONIC DISEASE; COLITIS, ULCERATIVE; COLONOSCOPY; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 21044457089     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.052316     Document Type: Article

References (25)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Podolsky D. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.
4. Veltkamp C, Tonkonogy SL, De Jong YP, et al. Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology 2001;120:900-13.
5. Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83.
6. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defense. FASEB J 1996;10:731-40.
7. Bernhard W, Postle AD, Linck M, et al. Composition of phospholipid classes and phosphatidylcholine molecular species or gastric mucosa and mucus. Biochim Biophys Acta 1995;1255:99-104.
8. Butler BD, Lichtenberger LM, Hills BA. Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983;244:G645-51.
9. DeSchryver-Kecskemeti K, Eliakim R, Carroll S, et al. Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989;84:1355-61.
10. Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by electrospray-tandem mass spectroscopy. Scand J Gastroent 2004;39:737-42.
11. Kao YC, Lichtenberger LM. A method to preserve extracellular surfactant-like phospholipids on the luminal surface of rodent gastric mucosa. J Histochem Cytochem 1990;38:427-31.
12. Bengmark S, Jeppsson B. Gastrointestinal surface protection and mucosa reconditioning. JPEN J Parenter Enteral Nutr 1995;19:410-15.
13. Ottlecz A, Romero JJ, Hazell SL, et al. Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies. Dig Dis Sci 1993;38:2071-80.
14. Weitkamp JH, Perez-Perez GI, Bode G, et al. Identification and characterization of Helicobacter pylori phospholipose C activity. Zentralbl Bakteriol 1993;280:11-27.
15. Foltz CJ, Fox JG, Cahill R, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 1998;3:69-78.
16. Fabia R, Ar'Rajab A, Willen R, et al. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion 1992;53:35-44.
17. Mourelle M, Guarner F, Malagelada JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 1996;110:1093-7.
18. Anes E, Kühnel M, Bos E, et al. Selected lipids can activate phagosome actin assembly and maturation leading to the killing of bpathagenic mycobacteria. Nat Cell Biol 2003;5:793-802.
19. Ehehalt R, Jochims C, Staffer S, et al. Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004;1682:63-71.
20. Nugent SG, Kumar D, Rampton DS, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
22. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
23. Truelove SC, Richards WD. Biopsy studies in ulcerative colitis. BMJ 1956;1:1315-18.
24. Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001;15:251-6.
25. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001;49:783-9.